RU2007123797A - Предотвращение формирования и/или стабилизации тромбов - Google Patents

Предотвращение формирования и/или стабилизации тромбов Download PDF

Info

Publication number
RU2007123797A
RU2007123797A RU2007123797/14A RU2007123797A RU2007123797A RU 2007123797 A RU2007123797 A RU 2007123797A RU 2007123797/14 A RU2007123797/14 A RU 2007123797/14A RU 2007123797 A RU2007123797 A RU 2007123797A RU 2007123797 A RU2007123797 A RU 2007123797A
Authority
RU
Russia
Prior art keywords
inhibitor
antibody
formation
fxii
trypsin
Prior art date
Application number
RU2007123797/14A
Other languages
English (en)
Other versions
RU2514878C2 (ru
Inventor
Бернхард НИЕСВАНДТ (DE)
Бернхард НИЕСВАНДТ
Томас РЕНЕ (DE)
Томас РЕНЕ
Original Assignee
Ксл Бехринг Гмбх (De)
Ксл Бехринг Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксл Бехринг Гмбх (De), Ксл Бехринг Гмбх filed Critical Ксл Бехринг Гмбх (De)
Publication of RU2007123797A publication Critical patent/RU2007123797A/ru
Application granted granted Critical
Publication of RU2514878C2 publication Critical patent/RU2514878C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (16)

1. Использование, по меньшей мере, одного антитела и/или одного ингибитора для ингибирования фактора коагуляции XII и предотвращения формирования и/или стабилизации тромбов и предотвращения, таким образом, внутрипросветного роста трехмерного тромба.
2. Использование по п.1, в котором указанное антитело представляет собой антитело анти-FXII.
3. Использование по п.1, в котором указанное антитело представляет собой ингибитор активизации FXII.
4. Использование по п.1, в котором указанный ингибитор представляет собой ингибитор протеазы.
5. Использование по п.1, в котором указанный ингибитор представляет собой ингибитор серин-протеазы.
6. Использование по п.3, в котором указанный ингибитор протеазы выбран из группы, содержащей ингибитор AT III, ангиотензин, ингибитор преобразования фермента, ингибитор С1, апротинин, ингибитор протеазы альфа-1, антиболевое средство ([(S)-1-карбокси-2-фенилэтил]-карбамоил-L-аргинал-L-вал-аргинал) ацетат Z-про-про-альдегид-диметил, DX88, леупептин, ингибиторы пролил олигопептидазы, такие как Fmoc-Ala-Pyr-CN, ингибитор корн-трипсина, мутанты бычьего панкреатического ингибитора трипсина, экотин, YAP (желтый одиночный белок антикоагулянта) и ингибитор-V трипсина семени тыквы и изоингибитор семени тыквы.
7. Использование антитела и/или ингибитора согласно любому из пп.1-4 в медицине.
8. Использование антитела и/или ингибитора по любому из пп.1-4 при изготовлении лекарственных средств.
9. Использование антитела и/или ингибитора по любому из пп.1-4 для лечения или профилактики условия или нарушений, связанных с формированием венозного или артериального тромба, особенно инсульт или инфаркт миокарда, воспаление, активация комплемента, фибринолиз, ангиогенез и/или болезни, связанные с вызванным FXII формированием кинина, такие как наследственная болезнь Квинке, бактериальные инфекции легкого, инфекции трипаносомы, гипотензивный шок, панкреатит, болезнь Шагаса или суставная подагра.
10. Фармацевтический препарат, содержащий, по меньшей мере, одно антитело и/или один ингибитор, который подходит для ингибирования фактора XII и который предотвращает формирование и/или стабилизацию патологических тромбов.
11. Препарат по п.8, в котором указанное антитело представляет собой антитело анти-FXII.
12. Препарат по п.8, в котором указанное антитело ингибирует активацию FXII.
13. Препарат по п.8, в котором указанный ингибитор представляет собой ингибитор протеазы.
14. Препарат по п.8, в котором указанное ингибитор представляет собой ингибитор серин-протеазы.
15. Препарат по п.10, в котором указанное ингибитор протеазы выбран из использования по п.3, в котором указанный ингибитор протеазы выбран из группы, содержащей ингибитор AT III, ангиотензин, ингибитор преобразования фермента, ингибитор С1, апротинин, ингибитор протеазы альфа-1, антиболевое средство ([(S)-1-карбокси-2-фенилэтил]-карбамоил-L-аргинал-L-вал-аргинал) ацетат Z-про-про-альдегид-диметил, DX88, леупептин, ингибиторы пролил олигопептидазы, такие как Fmoc-Ala-Pyr-CN, ингибитор корн-трипсина, мутанты бычьего панкреатического ингибитора трипсина, экотин, YAP (желтый одиночный белок антикоагулянта) и ингибитор-V трипсина семени тыквы и изоингибитор семени тыквы.
16. Использование фактора XII в качестве антитромбического средства ингибированным фактором XII, по меньшей мере, одним антителом и/или одним ингибитором и, следовательно, предотвращение формирования и/или стабилизации тромбов или роста тромба.
RU2007123797/14A 2004-12-23 2005-12-20 Предотвращение образования и/или стабилизации тромбов RU2514878C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030593 2004-12-23
EP04030593.0 2004-12-23
PCT/EP2005/013714 WO2006066878A1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization

Publications (2)

Publication Number Publication Date
RU2007123797A true RU2007123797A (ru) 2009-01-10
RU2514878C2 RU2514878C2 (ru) 2014-05-10

Family

ID=34927953

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007123797/14A RU2514878C2 (ru) 2004-12-23 2005-12-20 Предотвращение образования и/или стабилизации тромбов

Country Status (14)

Country Link
US (3) US8119137B2 (ru)
EP (2) EP1830924B1 (ru)
JP (1) JP5118492B2 (ru)
KR (1) KR101277097B1 (ru)
CN (1) CN101102819A (ru)
AU (1) AU2005318464B2 (ru)
BR (1) BRPI0519349A8 (ru)
CA (1) CA2591786C (ru)
DK (1) DK1830924T3 (ru)
ES (1) ES2407965T3 (ru)
MX (1) MX2007006997A (ru)
PL (1) PL1830924T3 (ru)
RU (1) RU2514878C2 (ru)
WO (1) WO2006066878A1 (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
TR201900937T4 (tr) 2002-08-28 2019-02-21 Dyax Corp Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
EP2109457B1 (en) * 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
CA2695012A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008315938B2 (en) * 2007-10-22 2014-11-27 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2145900A1 (en) 2008-07-15 2010-01-20 CSL Behring GmbH Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation
EP2103311A1 (en) 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2269597A1 (en) 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
US9150864B2 (en) * 2010-11-08 2015-10-06 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
DK2683397T3 (en) * 2011-03-09 2017-09-18 Csl Behring Gmbh FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP6253578B2 (ja) 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
EP2748616B1 (en) * 2011-08-23 2018-08-08 Synapse B.V. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces.
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
CN106456778A (zh) * 2014-06-18 2017-02-22 德国杰特贝林生物制品有限公司 在神经创伤性病患中使用因子xii抑制剂进行治疗
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
CN107810190A (zh) * 2015-04-28 2018-03-16 洛桑联邦政府综合工科学校（Epfl) 酶活化因子XII (FXIIa)的新型抑制剂
JP7068160B2 (ja) 2015-07-21 2022-05-16 武田薬品工業株式会社 第ＸＩＩａ因子のモノクローナル抗体阻害剤
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
AU2017247004B2 (en) * 2016-04-06 2022-07-07 Csl Limited Method of treating atherosclerosis
AU2018382222B2 (en) 2017-12-15 2025-09-04 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
MA52966A (fr) * 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
CN113423465B (zh) * 2018-11-28 2024-12-06 俄勒冈健康与科学大学 治疗性的因子xii抗体
CN114502531B (zh) 2019-07-08 2024-05-24 雷佐鲁特公司 制备血浆激肽释放酶抑制剂的方法
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
US12018261B2 (en) 2020-12-18 2024-06-25 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor XII
AU2024291721A1 (en) 2023-07-19 2026-01-22 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1994020535A1 (en) * 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
JP3929484B2 (ja) 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
GB9800817D0 (en) 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
EP1084270B1 (en) * 1998-06-08 2004-08-25 The University Of Vermont And State Agricultural College Methods for assaying clotting in plasma
AU760735B2 (en) * 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (en) * 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US20060093595A1 (en) 2002-07-05 2006-05-04 Mahesh Jayachandra Methods, compositions and kits for treating damage to excitable tissue
TR201900937T4 (tr) * 2002-08-28 2019-02-21 Dyax Corp Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
PT1626736T (pt) 2003-05-16 2020-10-13 Pharming Intellectual Property B V Inibidor c1 com curta meia-vida para tratamento transitório
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
GB0411145D0 (en) 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
GB0418877D0 (en) 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
EP1669074B1 (en) 2004-12-01 2010-06-02 Par Pharmaceuticals, Inc. Use of megestrol acetate for improving heart function and the treatment of heart insufficiency

Also Published As

Publication number Publication date
CN101102819A (zh) 2008-01-09
CA2591786C (en) 2013-07-16
BRPI0519349A2 (pt) 2009-01-20
US20130164301A1 (en) 2013-06-27
DK1830924T3 (da) 2013-05-21
JP5118492B2 (ja) 2013-01-16
EP2272565A2 (en) 2011-01-12
EP1830924B1 (en) 2013-02-27
US20120148688A1 (en) 2012-06-14
EP1830924A1 (en) 2007-09-12
US8715672B2 (en) 2014-05-06
ES2407965T3 (es) 2013-06-17
PL1830924T3 (pl) 2013-08-30
US20080254039A1 (en) 2008-10-16
CA2591786A1 (en) 2006-06-29
AU2005318464B2 (en) 2012-02-23
KR20070092303A (ko) 2007-09-12
BRPI0519349A8 (pt) 2017-09-12
AU2005318464A1 (en) 2006-06-29
KR101277097B1 (ko) 2013-06-20
MX2007006997A (es) 2007-10-10
EP2272565A3 (en) 2012-03-28
JP2008525342A (ja) 2008-07-17
US8119137B2 (en) 2012-02-21
RU2514878C2 (ru) 2014-05-10
WO2006066878A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
JP2008525342A5 (ru)
Schmaier et al. The plasma kallikrein–kinin system: its evolution from contact activation
Smith et al. How it all starts: Initiation of the clotting cascade
AU2005318464B2 (en) Prevention of thrombus formation and/or stabilization
Hillmeister et al. The kallikrein-kinin system.
US7199113B2 (en) Pharmaceutically active compounds and methods of use thereof
Brooks et al. Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion.
Mukaiyama et al. Abdominal aortic aneurysm complicated with chronic disseminated intravascular coagulopathy: a case of surgical treatment
EA013078B1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
Jeske et al. Pharmacology of argatroban
Hellstern et al. Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency
Gomazkov Damage to the vascular endothelium as a leading mechanism of COVID-19 systemic pathology
Dellalibera-Joviliano et al. Kinin system in lupus nephritis
Mukherjee et al. Medical and diagnostic applications of snake venom proteomes
Haberland The role of kininogenases, kinin formation and kininogenase inhibition in post traumatic shock and related conditions
Malyszko et al. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients
Marks Coagulation disorders in the ICU
Sanchez et al. Surface-adsorbed fibrinogen and fibrin may activate the contact activation system
Sommoggy et al. Coagulation in aortofemoral bifurcation bypass grafting
Bhagat et al. Delayed massive pulmonary thromboembolic phenomenon following envenomation by Mojave rattlesnake (Crotalus scutulatus)
Sánchez et al. On the control of the plasma contact activation system on human endothelium: comparisons with heparin surface
Aasen et al. Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis
Porte et al. A comparative study on changes in hemostasis in orthotopic and auxiliary liver transplantation in pigs
Peterson et al. Anticoagulation strategies for venous thromboembolism
CN109316599A (zh) 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20101019

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20110812

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20121101

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20131024